Top Page
SinoMab Bioscience Ltd.
(3681)
SinoMab Bioscience Ltd. (3681) vs. iShares MSCI Hong Kong ETF (EWH)
SinoMab Bioscience Ltd. Business Overview & Revenue Model
SinoMab Bioscience Ltd. Financial Statement Overview
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 2.03M | 1.36M | 4.03M | 26.66M | 12.76M | Gross Profit |
| 543.00K | 422.00K | 4.03M | 26.66M | 12.76M | EBIT |
| -161.35M | -229.57M | -258.93M | -305.86M | -162.65M | EBITDA |
| -142.79M | -200.46M | -244.29M | -296.43M | -158.61M | Net Income Common Stockholders |
| -185.14M | -243.11M | -284.16M | -288.19M | -122.60M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 106.88M | 234.66M | 422.38M | 589.53M | 916.20M | Total Assets |
| 753.10M | 847.79M | 1.01B | 1.04B | 1.13B | Total Debt |
| 482.27M | 450.81M | 357.18M | 275.46M | 97.84M | Net Debt |
| 420.37M | 247.14M | 11.47M | -287.52M | -712.53M | Total Liabilities |
| 560.19M | 552.20M | 498.77M | 361.43M | 142.51M | Stockholders Equity |
| 192.91M | 295.58M | 509.57M | 680.23M | 987.01M |
| Cash Flow | Free Cash Flow | |||
| -172.30M | -237.74M | -413.29M | -345.30M | -217.29M | Operating Cash Flow |
| -130.80M | -133.85M | -300.54M | -147.06M | -141.34M | Investing Cash Flow |
| -94.48M | -96.92M | -81.36M | -137.70M | -179.22M | Financing Cash Flow |
| 73.27M | 82.27M | 102.28M | 57.52M | -18.81M |
SinoMab Bioscience Ltd. Technical Analysis
SinoMab Bioscience Ltd. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | HK$98.06B | 27.18 | 8.17% | ― | 7.52% | -1.92% | |
58 Neutral | HK$3.23B | 18.36 | 4.47% | ― | -9.75% | ― | |
55 Neutral | HK$82.62B | ― | -8.98% | ― | -54.66% | -123.11% | |
53 Neutral | $5.22B | 3.33 | -44.36% | 7.55% | 16.78% | -0.12% | |
53 Neutral | HK$2.51B | ― | -75.64% | ― | 42.21% | 29.52% | |
52 Neutral | HK$32.88B | ― | -19.78% | ― | 25.96% | 39.58% | |
46 Neutral | €1.97B | ― | -31.66% | ― | 30.54% | 46.26% |
SinoMab Bioscience Ltd. Corporate Events
SinoMab BioScience Limited announced the resignation of Mr. Shanchun Wang from his position as an executive director and from directorships in certain subsidiaries, effective June 9, 2025. Mr. Wang resigned to focus on personal commitments and confirmed no disagreements with the board, indicating a smooth transition. This change in leadership may impact the company’s strategic direction, but the company has not indicated any immediate operational disruptions.
SinoMab BioScience Limited has announced the composition of its board of directors and their respective roles within the company. This update includes the appointment of Dr. Shui On Leung as both Chairman and CEO, alongside a mix of executive, non-executive, and independent non-executive directors. The announcement also details the membership of the board’s committees, highlighting the company’s structured governance approach, which could enhance its strategic decision-making and operational oversight.
SinoMab BioScience Limited has announced the postponement and change of venue for its 2025 Annual General Meeting (AGM) due to administrative reasons. Originally scheduled for June 13, 2025, the AGM will now take place on June 30, 2025, at a new location in Hong Kong. Additionally, the book closure period for determining shareholders’ entitlement to attend and vote at the AGM has been adjusted. The withdrawal of an ordinary resolution concerning the re-election of an independent director, due to his passing, was also noted. These changes are expected to impact the company’s operational schedule and shareholder engagement.
SinoMab BioScience Limited announced the passing of Mr. Dylan Carlo Tinker, an independent non-executive director and a member of both the audit and nomination committees. This unfortunate event has left the company temporarily non-compliant with the Hong Kong Stock Exchange’s listing rules, as the nomination committee no longer has a majority of independent non-executive directors. The company plans to appoint a suitable replacement within three months to rectify this situation. Additionally, due to Mr. Tinker’s passing, the resolution for his re-election will be withdrawn from the upcoming annual general meeting agenda.
SinoMab BioScience Limited has announced the composition of its board of directors and their respective roles within the company. This announcement provides clarity on the leadership structure, which is crucial for stakeholders and investors as it may influence the company’s strategic direction and governance.
SinoMab BioScience Limited has successfully completed the subscription of new shares under a general mandate, issuing a total of 112,810,817 shares. This issuance represents approximately 9.37% of the company’s enlarged share capital and has raised net proceeds of about HK$123,956,911, which will be used as previously disclosed. This move is expected to impact the company’s shareholding structure and potentially enhance its financial position and market presence.
SinoMab BioScience Limited has entered into 26 subscription agreements with independent third-party subscribers to issue a total of 112,810,817 new shares at a price of HK$1.10 each. This move, which does not require shareholder approval, aims to raise approximately HK$124 million in gross proceeds, with net proceeds intended for strategic purposes outlined by the company. The issuance represents about 10.33% of the company’s current share capital and is expected to enhance SinoMab’s financial position and market presence.
SinoMab BioScience Limited has announced its 2025 Annual General Meeting scheduled for June 13, 2025. Key agenda items include the re-election of several directors, the re-appointment of Ernst & Young as auditors, and granting the board mandates to buy back shares and issue new shares. These resolutions are aimed at strengthening the company’s governance and providing flexibility in capital management, potentially impacting its market operations and shareholder value.
SinoMab BioScience Limited announced positive topline results from its Phase 1b clinical trial of SM17 in China for treating moderate-to-severe atopic dermatitis. The trial demonstrated significant efficacy in pruritus reduction and skin clearance, with no serious adverse events reported, positioning SM17 as a promising treatment option in the competitive dermatology market.
SinoMab BioScience Limited announced its audited consolidated annual results for the year ended December 31, 2024, highlighting significant progress in clinical trials and pipeline development. The company’s flagship product, SM03, is in the final review stage for treating rheumatoid arthritis, while SM17 has shown promising results in treating atopic dermatitis. Financially, the company reduced its annual loss by RMB58.0 million, attributed to decreased R&D costs, and raised HKD73.2 million through new share subscriptions. However, the board does not recommend a final dividend for the reporting period.